Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 5/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.43 |
| ▸ | LCK | P06239 | 4/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690794 | 0.82 | S1PR3 (0.43) | OGAP2RY2S1PR3CDK2CCNE1 | |
| SCHEMBL10125043 | 0.82 | S1PR3 (0.43) | OGAP2RY2S1PR3CDK2CCNE1 | |
| SCHEMBL34467551 | 0.81 | P2RY2 (0.42) | P2RY2S1PR3CDK2CCNE1CDK5 | |
| SCHEMBL19003723 | 0.81 | CCNE1 (0.42) | P2RY2CDK2CCNE1CDK5LCK | |
| SCHEMBL14145315 | 0.80 | S1PR3 (0.41) | OGAP2RY2S1PR3CDK2CCNE1 | |
| SCHEMBL21394886 | 0.80 | P2RY2 (0.53) | P2RY2CDK2CCNE1CDK5FFAR2 | |
| SCHEMBL19003795 | 0.79 | CYP3A4 (0.43) | P2RY2S1PR3CDK2CCNE1CDK5 | |
| SCHEMBL17998701 | 0.78 | CDK2 (0.61) | P2RY2CDK2CCNE1CDK5LCK | |
| SCHEMBL34467357 | 0.78 | STAT3 (0.41) | P2RY2CDK2CCNE1CDK5LCK | |
| SCHEMBL21394890 | 0.76 | S1PR3 (0.46) | P2RY2S1PR3CDK2CCNE1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174675-A9 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174675-A9 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1G, SCNN1B | OGA 2812/4885P2RY2 80/4885S1PR3 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.